← Oncology Approval Tracker

FDA DECISION ·

Sarclisa Escena + VRd

subcutaneous isatuximab-irfc with bortezomib, lenalidomide and dexamethasone · Sanofi

FDA approvalNew formulationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplant.

LAMPGEN ANALYSIS

Why it matters

The new formulation also applies to a front-line regimen in transplant-ineligible patients. The IsaSocut evidence is a separate single-arm study from the randomized route comparison in relapsed disease.

What research teams should watch

Document transplant eligibility and align each drug in the regimen with its administration schedule. The route change should be reflected in pharmacy and nursing workflows.

PRIMARY RECORDS

Sources